Dianthus Therapeutics, Inc.
DNTH
Kedudukan dalam Saham
#3909
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Harga Saham
$75.21
Modal Pasaran
$4.21B
Perubahan (1 hari)
4.33%
Perubahan (1 tahun)
110.98%
Negara
US
Perdagangan Dianthus Therapeutics, Inc. (DNTH)
Kategori
Healthcare
Sejarah pecahan saham untuk Dianthus Therapeutics, Inc. (DNTH)
Saham Dianthus Therapeutics, Inc. (simbol: DNTH) telah mengalami sejumlah 1 pecahan saham.
Pecahan saham terkini berlaku pada Sep 12, 2023.
Satu saham DNTH yang dibeli sebelum Sep 12, 2023 kini bersamaan dengan 0.0625 saham DNTH.
Pecahan saham terkini berlaku pada Sep 12, 2023.
Satu saham DNTH yang dibeli sebelum Sep 12, 2023 kini bersamaan dengan 0.0625 saham DNTH.
Senarai pecahan saham
| Tahun | Pecahan | Gandaan | Gandaan Kumulatif |
|---|---|---|---|
| 2023-09-12 | 1:16 | x0.0625 | x0.0625 |
Pecahan saham untuk syarikat pesaing atau serupa
| Syarikat | Bilangan pecahan saham | Gandaan Kumulatif | Negara |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
